FGF-23 and Endothelial Dysfunction in Diabetic Proteinuric Patients

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Mahmut Ilker Yilmaz, Gulhane School of Medicine
ClinicalTrials.gov Identifier:
NCT01703234
First received: October 4, 2012
Last updated: October 6, 2012
Last verified: October 2012
  Purpose

There is no data about the effects of Renin angiotensin system blockage (RAS) on FGF23 and ADMA levels in diabetic patients with proteinuria. The aim of this study was to find out whether the beneficial effects of RAS blockage in diabetic proteinuria has any relation with the alteration of ADMA and FGF-23 levels. We searched for the effects of ACE inhibitor ramipril on the clinical and laboratory parameters of diabetic patients with proteinuria.


Condition Intervention Phase
Proteinuria
Diabetic Nephropathy
Chronic Kidney Disease
Drug: Ramipril
Phase 4

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by Gulhane School of Medicine:

Primary Outcome Measures:
  • Flow Mediated Dilatation

Secondary Outcome Measures:
  • FGF-23

Enrollment: 78
Study Start Date: January 2008
Study Completion Date: April 2009
Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Ramipril Drug: Ramipril
ramipril 10 mg/day during 3 months

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • CKD stage 1 patients
  • Older than 18 years of age
  • Type 2 Diabetic patients
  • Proteinuria

Exclusion Criteria:

  • History of coronary artery disease
  • Smokers
  • Taking statins or renin-angiotensin blockers
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01703234

Locations
Turkey
Gulhane School of Medicine
Ankara, Turkey
Sponsors and Collaborators
Gulhane School of Medicine
  More Information

No publications provided

Responsible Party: Mahmut Ilker Yilmaz, Assoc.Prof., Gulhane School of Medicine
ClinicalTrials.gov Identifier: NCT01703234     History of Changes
Other Study ID Numbers: GATARAMFGF232012
Study First Received: October 4, 2012
Last Updated: October 6, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Gulhane School of Medicine:
FGF-23 , ramipril, endothelial dysfunction

Additional relevant MeSH terms:
Diabetic Nephropathies
Kidney Diseases
Proteinuria
Renal Insufficiency, Chronic
Urologic Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Urination Disorders
Urological Manifestations
Signs and Symptoms
Renal Insufficiency
Ramipril
Angiotensin-Converting Enzyme Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Antihypertensive Agents
Cardiovascular Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on August 28, 2014